A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-01

Study Completion Date

2023-02-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

Additionally, the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC patients as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

NCT05943795

Non-small Cell Lung Adenocarcinoma Squamous Cell Carcinoma of Lung

ACTIVE_NOT_RECRUITING PHASE3

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

NCT07217301

iO Resistant sqNSCLC

RECRUITING PHASE3

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

NCT04056949

Extensive-Stage Small Cell Lung Cancer

UNKNOWN PHASE2

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

NCT03629925

Squamous NSCLC

COMPLETED PHASE3

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

NCT05325684

Efficacy Safety

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBI308

injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria

Group Type EXPERIMENTAL

IBI308

Intervention Type DRUG

Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

docetaxel

injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria

Group Type ACTIVE_COMPARATOR

Docetaxel

Intervention Type DRUG

As 2nd line treatment to subjects with squamous NSCLC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IBI308

Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

Intervention Type DRUG

Docetaxel

As 2nd line treatment to subjects with squamous NSCLC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects with Histologically or cytologically confirmed squamous cell NSCLC
2. Subjects with stage IIIB/stage IV or recurrent disease (not suitable for definitive concurrent chemoradiotherapy) (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) after failure of first-line platinum-based therapy; Subjects who developed recurrent disease \<6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy also could also be eligible.
3. At lease one measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
4. Age ≥ 18 and ≤ 75
5. ECOG performance status 0-1
6. Life expectancy of at least 12 weeks
7. Adequate organ and bone marrow function

1. CBC: absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelet count (PLT) ≥ 100 × 109 / L; hemoglobin content (HGB) ≥ 9.0 g / dL.
2. Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum albumin ≥ 28 g / L.
3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate (Ccr) ≥ 40 mL / min (calculated using Cockcroft / Gault equation) Female:CrCl= (140-Age) x Weight(kg) x 0.85 72 x Serum creatinine (mg/dL) Male:CrCl= (140-Age) x Weight(kg) x 1.00 72 x Serum creatinine (mg/dL)
8. Subjects of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study treatment.
9. Voluntarily signed written informed consent form, willing and able to comply with scheduled visits and other requirements of the study

Exclusion Criteria

1. EGFR mutation and ALK rearrangement
2. Mixed adeno-squamous carcinoma or other pathological type
3. Prior therapy with anti-PD-1,anti-PD-L1,anti-CTLA4 antibody or docetaxel
4. Have received following treatment:

1. Received any investigational agent within 4 weeks of the first dose of study treatment.
2. Received any anti-tumor therapy (chemotherapy, targeted therapy, tumor immunotherapy or arterial embolization) within 3 weeks of the first dose of study treatment.
3. Received radiotherapy within 4 weeks of the first dose of study treatment.
4. Received systemic treatment with high-dose corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive drugs within 4 weeks of first dose. Inhaled or topical steroids and adrenal replacement steroid are permitted in the absence of active autoimmune disease.
5. Received attenuated live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.
6. Received major surgery (such as craniotomy, thoracotomy or laparotomy) within 4 weeks of the first dose of study drugs or open wound, ulcer or fracture.
5. Unrecovered toxicity (grade \>1, according to NCI CTCAE 4.03) due to prior anti-tumor therapy before the first dose of study treatment.
6. Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment.
7. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation
8. Known allergic or hypersensitive to docetaxel, any monoclonal antibody or any other components used in their preparation.
9. Hemoptysis within 4 weeks of randomization (≥ 1/2 spoon per time).
10. Received thoracic radiotherapy \>30Gy within 6 months or palliative radiotherapy (brain or bone metastasis) ≤30Gy within 7 days of randomization.
11. Symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis. Subjects should have stable disease more than 4 weeks from first dose of study treatment, with neurological symptoms returned to NCI CTCAE 4.03 grade 0 or 1, are permitted to enroll.
12. Subjects with a history of interstitial lung disease
13. Superior vena caval obstruction syndrome;
14. Uncontrolled third space effusion, eg. ascites or pleural effusion.
15. Uncontrolled concomitant disease, including but not limited to :

1. Active or poorly controlled severe infection
2. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)
3. Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection
4. Active tuberculosis
5. Symptomatic congestive heart failure (New York Heart Association grade III-IV) or symptomatic, poorly controlled arrhythmia
6. Uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg)
7. Prior arterial thromboembolism event, including myocardial infarction, unstable angina, stroke and transient ischemic attack, within 6 months of enrollment
8. Concomitant disease needs anticoagulant therapy
9. Uncontrolled hypercalcemia(Ca2+\>1.5mmol/L or Ca \>12mg/dl or corrected Serum Calcium \>ULN),or Symptomatic hypercalcemia during diphosphonate therapy
10. Other primary malignancy, with the exception of: (radical Non-melanoma skin cancer or cured cervical in-situ carcinoma;)
16. Subjects with other diseases or abnormal Lab test results which might increase the risk of enrollment and treatment or Interfere with the interpretation of study results could be excluded according to the judgments of investigator.
17. Women who are pregnant or nursing

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No